MedTrace Logo

A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

NCT03760614 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2021-01-15

No results posted yet for this study

Summary

The main purpose of this study is to find the best dose of entinostat when given in combination with FOLFOX for pancreatic cancer.

Conditions

  • Pancreas Cancer

Interventions

DRUG

Entinostat

Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.

DRUG

FOLFOX regimen

FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-31
Primary Completion
2022-07-31
Completion
2022-11-30
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03760614 on ClinicalTrials.gov